Increasing prevalence and incidence of neurological disorder is propelling the growth of the pupillometer market. Individuals with anxiety issues, depression, Parkinson’s disease, and Autism spectrum disorder have shown abnormal pupillometry responses towards the stimuli. According to the Parkinson's News Today, Parkinson’s disease is the second most common age-related neurodegenerative disorder after Alzheimer’s disease. An estimated seven to 10 million people worldwide have Parkinson’s disease. The prevalence of the disease ranges from 41 people per 100,000 in the fourth decade of life to more than 1,900 people per 100,000 among those who are 80 and older.
1. In February 2021, NeurOptics, the provider of pupillometry, has launched its Pupillometry Education Symposiums platform, which includes a series of both product and clinical-focused presentations that demonstrate the essential role pupillometry and the Neurological Pupil index™ (NPi®) play in the assessment and screening of patients at risk of neurological injury
2. In November 2017, Johnson & Johnson Vision announced a series of product milestones and launches supporting its growing portfolio, designed to improve and restore sight for patients worldwide